grant
Genetic Engineering of Myeloid Cells to Treat Cancer
Organization UNIVERSITY OF CALIFORNIA, SAN FRANCISCOLocation SAN FRANCISCO, UNITED STATESPosted 1 Aug 2025Deadline 31 Jul 2028
NIHUS FederalResearch GrantFY2025Adaptive Immune SystemAntigen PresentationAntigensCRISPRCRISPR/Cas systemCancersCell BodyCell SurvivalCell TherapyCell ViabilityCellsCellular biologyClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsCross PresentationDNA mutationDendritic CellsDysfunctionEngineeringFunctional disorderGenesGenetic ChangeGenetic EngineeringGenetic Engineering BiotechnologyGenetic Engineering Molecular BiologyGenetic defectGenetic mutationHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHeterogeneityHumanImmuneImmune mediated therapyImmunesImmunocompetentImmunologic ReceptorsImmunological ReceptorsImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyInfiltrationInnate Immune SystemKnock-outKnockoutLentivirinaeLentivirusLibrariesLiquid substanceMacrophageMalignant Hematologic NeoplasmMalignant NeoplasmsMalignant TumorMedicineMembrane Protein GeneMembrane ProteinsMembrane-Associated ProteinsModern ManMutationMyelogenousMyeloidMyeloid CellsMφPhysiopathologyPre-Clinical ModelPreclinical ModelsReceptor ProteinRecombinant DNA TechnologyRefractoryResistanceRoleSignaling MoleculeSolid NeoplasmSolid TumorSurface ProteinsSystemT cell based immune therapyT cell based therapeuticsT cell based therapyT cell directed therapiesT cell immune therapyT cell immunotherapyT cell targeted therapeuticsT cell therapyT cell treatmentT cell-based immunotherapyT cell-based treatmentT cellular immunotherapyT cellular therapyT lymphocyte based immunotherapyT lymphocyte based therapyT lymphocyte therapeuticT lymphocyte treatmentT-Cell ActivationT-CellsT-LymphocyteT-cell therapeuticsT-cell transfer therapyTechniquesTestingToxic effectToxicitiesTumor AntigensTumor CellTumor ImmunityTumor-Associated AntigenVeiled Cellsacquired immune systemactivate T cellsadaptive immunityadoptive T cell transferadoptive T lymphocyte transferadoptive T-cell therapyanti-tumor immunityantitumor immunityautoinflammatory diseasesautoinflammatory disordersbase editingcancer antigenscancer immunitycancer microenvironmentcell based interventioncell biologycell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapycytokinedelivery vectordelivery vehicledesigndesigningfluidgene complementationgene editing methodgene editing methodologygene editing strategygene editing techniquesgene-editing approachgenetically engineeredgenome mutationhumanized micehumanized mousehypoimmunityimmune competentimmune deficiencyimmune microenvironmentimmune receptorimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunodeficiencyimmunogenimmunogenicityimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive responseimmunosuppressive tumor microenvironmentin vivoinnovateinnovationinnovativeliquidmalignancymanufacturemouse modelmurine modelmutantneoplasm/cancerneoplastic cellnew approachesnovelnovel approachesnovel strategiesnovel strategynucleofectionpathophysiologypolarized cellpreservationprogramsreceptorresistantresponsesocial rolesuccesstherapeutic T-cell platformtherapeutic candidatethymus derived lymphocytetooltransduction efficiencytumortumor immune microenvironmenttumor microenvironmenttumor-immune system interactionstumor-specific antigen
Description preview
PROJECT SUMMARY/ABSTRACT
Background: Despite the success of T cell therapies in treating hematologic malignancies, solid tumors
remain a significant challenge due to their dense fibrotic stroma, immunosuppressive microenvironments, and
antigen heterogeneity. Current adaptive cell therapy approaches struggle to overcome these barriers,
highlighting…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click